Placebo-Controlled Study of Mometasone Furoate Nasal Spray (MFNS) 200 mcg Once Daily (QD) in the Treatment of Seasonal Allergic Rhinitis (Study P05067)(COMPLETED)

Summary

This study is designed to assess the effectiveness of mometasone furoate nasal spay (MFNS) once daily (QD) compared with placebo in subjects with seasonal allergic rhinitis (SAR) in reducing the total nasal symptom score and the total ocular symptom score.

Timeline

Start

2007-03

Primary completion

2007-06

Completion

2007-06

Outcome

Mixed primary results

registry Change from Baseline in TNSS: -2.36 NCT00453063 ↗

registry Change from Baseline in TNSS: -1.71 NCT00453063 ↗

registry Mometasone Furoate Nasal Spray (MFNS) vs Placebo; p = 0.001; ANCOVA NCT00453063 ↗

registry Change from Baseline in TOSS: -1.52 NCT00453063 ↗

registry Change from Baseline in TOSS: -1.36 NCT00453063 ↗

registry Mometasone Furoate Nasal Spray (MFNS) vs Placebo; p = 0.304; ANCOVA NCT00453063 ↗

Publications

• Results Bielory L, Chun Y, Bielory BP, Canonica GW. Impact of mometasone furoate nasal spray on individual ocular symptoms of allergic rhinitis: a meta-analysis. Allergy. 2011 May;66(5):686-93. doi: 10.1111/j.1398-9995.2010.02543.x. Epub 2011 Jan 25.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Mometasone furoate	Other / unclassified	200 ug	Intranasal

Indications